Physician profile
Stuart Horowitz
NPI 1972661155
$9,738.91
in general payments reported to CMS, 2019-2025
46 companies · $1,970 in 2025
The $1,970 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,215 · 2020: $927 · 2021: $1,594 · 2022: $963 · 2023: $1,391 · 2024: $1,678 · 2025: $1,970.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,039.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,038.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,411.14 | 2019-2025 | |
| Phathom Pharmaceuticals, INC. | $923.52 | 2023-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $600.37 | 2019-2025 | Xifaxan, Trulance |
| Novo Nordisk INC | $468.57 | 2019-2024 | Ozempic, Rybelsus |
| Arbor Pharmaceuticals, INC. | $455.65 | 2019-2021 | |
| Glaxosmithkline, LLC. | $443.37 | 2019-2025 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $407.19 | 2019-2025 | Airsupra, Farxiga |
| Amarin Pharma, INC. | $370.15 | 2019-2023 | |
| Kowa Pharmaceuticals America, INC. | $287.75 | 2019-2023 | Livalo, Seglentis |
| Pfizer INC. | $281.52 | 2019-2025 | |
| Amgen INC. | $279.50 | 2021-2025 | Repatha, Otezla, Repatha |
| Daiichi Sankyo INC. | $269.36 | 2023-2024 | Injectafer |
| Janssen Pharmaceuticals, INC | $262.27 | 2020-2023 | Xarelto |
| Novartis Pharmaceuticals Corporation | $234.68 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $195.45 | 2019-2024 | Ofev, Jardiance |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $185.32 | 2019-2021 | |
| Lilly USA, LLC | $169.98 | 2019-2023 | Jardiance, Emgality |
| Madrigal Pharmaceuticals | $133.36 | 2025 | Rezdiffra |
| Janssen Biotech, INC. | $128.84 | 2023-2025 | Stelara, Tremfya, Simponi |
| Ardelyx, INC. | $124.84 | 2024-2025 | Ibsrela |
| Renalytix Ai, INC. | $111.87 | 2024-2025 | Kidneyintelx Blood Collection Convenience Kit |
| E.R. Squibb & Sons, L.L.C. | $102.99 | 2019-2023 | Eliquis |
| Abbott Laboratories | $84.06 | 2021-2025 | Freestyle Libre 3 |
| Redhill Biopharma INC. | $63.70 | 2021-2023 | |
| Exact Sciences Corporation | $63.08 | 2023-2024 | Cologuard Collection Kit |
| Esperion Therapeutics, INC. | $56.43 | 2024-2025 | Nexletol |
| Allergan, INC. | $56.31 | 2019-2020 | |
| Boston Scientific Corporation | $54.32 | 2025 | Watchman Flx |
| Aimmune Therapeutics, INC. | $47.61 | 2024 | |
| Medicomp INC | $44.05 | 2024 | Telepatch Cardiac Monitor |
| Biohaven Pharmaceutical Holding Company LTD. | $41.09 | 2022 | |
| Sanofi Pasteur INC. | $39.82 | 2022-2025 | |
| Astellas Pharma US INC | $36.45 | 2020-2021 | |
| Scilex Pharmaceuticals INC. | $36.11 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $34.67 | 2021 | |
| Evoke Pharma, INC. | $31.97 | 2022-2023 | Gimoti |
| Sanofi-Aventis U.S. LLC | $29.76 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $27.68 | 2025 | Entyvio |
| Heartflow, INC. | $24.49 | 2024 | |
| Genentech USA, INC. | $22.06 | 2019 | |
| Xeris Pharmaceuticals, INC. | $20.30 | 2024 | Gvoke Hypopen |
| Hologic Sales and Service, LLC | $20.19 | 2023 | Thinprep 2000 Processor |
| Bardy Diagnostics, INC. | $16.00 | 2020 | |
| Siemens Medical Solutions USA, INC. | $15.98 | 2019 | |
| Philips North America LLC | $14.17 | 2021 | |
| Seqirus USA INC | $10.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stuart Horowitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.